Atea Pharmaceuticals Q4 Earnings Call Highlights

Atea Pharmaceuticals (NASDAQ: AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its fourth quarter and full-year 2025 financial results conference call. Management also discussed commercial launch preparations for HCV and reviewed the company's year-end cash position and spending outlook.